Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioLineRx, a clinical stage drug development company, and Yissum, the technology transfer company of the Hebrew University of Jerusalem, have signed a worldwide exclusive licensing agreement.
Subscribe to our email newsletter
Pursuant to the terms of the agreement, BioLineRx will develop and commercialize BL-5040, a new anti-hormone for the treatment of inflammatory diseases. Rights to the compound were also obtained from Tel Aviv Sourasky Medical Center. Financial terms of the license were not disclosed.
Morris Laster, CEO of BioLineRx, said: “BL-5040 is part of the new and exciting biological approach for treating these debilitating diseases, and preclinical trials look very promising.
“We look forward to further developing this drug candidate, which we believe may present a new and improved treatment for inflammatory disease and could have a positive impact on millions of lives.”